MEDIOS AG
DGAP-Ad-hoc: Medios AG / Key word(s): Preliminary Results/Forecast Medios AG exceeds revenue and EBT pre1 forecasts for financial year 2021 - Executive Board optimistic for financial year 2022 Berlin, March 3, 2022 - Due to stronger than expected organic growth, Medios AG ("Medios") has slightly exceeded its revenue and EBT pre1 forecasts for the financial year 2021. According to preliminary calculations (IFRS), consolidated revenue more than doubled year-on-year to ?1,357.4 million (previous year ?626.5 million) in the period from January to December 2021. At the same time, operating profit increased disproportionately: EBITDA pre1 rose to ?38.4 million (previous year ?15.1 million), an increase of 155.3%. EBT pre1 rose by 169.7% to ?32.3 million (previous year ?12.0 million). Consolidated revenue was forecasted to be between ?1.2 and 1.3 billion, EBITDA pre1 between ?38.0 and 39.0 million and EBT pre1 between ?31.0 and 32.0 million. The strong increase in revenue and earnings in the 2021 financial year is due in particular to the full consolidation of Cranach Pharma GmbH. The complete and audited consolidated financial statements of Medios AG will be published with the Annual Report 2021 on March 29, 2022. The Executive Board is optimistic for the 2022 financial year. With the acquisition of the NewCo Pharma Group, Medios significantly strengthens the Patient-Specific Therapies segment and expects this to lead to a significant and sustainable increase in the profit margins of the entire Medios Group. In addition, Medios expects continued dynamic organic growth due to the high demand for Specialty Pharma drugs and the planned further innovations in the area of patient-specific therapies. In the 2022 financial year, Medios expects revenue in the amount of ?1.45 - 1.60 billion. This corresponds to an increase of 6.8 - 17.9% compared to the previous year. EBITDA pre1 is expected to be in the range of ?52.0 - 58.0 million. This corresponds to an increase of 35.3 - 50.9% compared with the previous year. With revenue and EBITDA pre1, the system of key figures for managing the business success of Medios AG has comprised only two financial key figures for strategy and decision-making as well as for measuring the operating business success since January 1, 2022. The previously additionally used key figures earnings before taxes (EBT) and earnings before taxes and nonrecurring items (EBT pre1) are no longer considered for this purpose. 1 EBITDA is defined as consolidated earnings before interest, income taxes, depreciation and amortization. EBT is defined as net earnings before income taxes. EBITDA pre and EBT pre are each adjusted for extraordinary expenses for stock options, M&A activities, and amortization of the customer base as well as on the goodwill. Notifying person: Matthias Gaertner, Chief Executive Officer of Medios AG Contact Information and Explanation of the Issuer to this News: About Medios AG Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). Contact
03-March-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 - 800 |
| Fax: | +49 30 232 566 - 801 |
| E-mail: | ir@medios.ag |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf |
| EQS News ID: | 1293875 |
| End of Announcement | DGAP News Service |
1293875 03-March-2022 CET/CEST
